【JP:206A】Stock Price

PRISM BioLab conducts research and development of new drugs targeting protein-protein interactions within cells—an area that has been difficult to address through traditional drug discovery. The company operates a drug discovery platform equipped with a three-dimensional small molecule library and experimental and analytical capabilities, advancing from hit compound identification through optimization to clinical candidate compounds.

The company pursues two parallel business models: an in-house development model where it enhances value internally before licensing to pharmaceutical companies, and a co-development model where it advances programs jointly with pharmaceutical partners. Major partners include domestic and international pharmaceutical companies such as Eisai and Ohara Pharmaceutical. Revenue streams include joint research fees, upfront payments, milestone payments at development milestones, and royalties following market launch. In-house development requires significant upfront investment and carries higher risk, but offers substantial returns upon success, while co-development reduces investment and enables earlier revenue generation.

The business is divided into in-house development and co-development segments. The pipeline includes E7386 (in clinical trials), licensed to Eisai, and PRI-724 (in clinical development in the fibrosis field), licensed to Ohara Pharmaceutical. The company combines compound synthesis technology, evaluation equipment, computational chemistry, and AI to run multiple drug discovery programs in parallel, aiming to improve success rates and generate continuous drug discovery outcomes.

PRISM BioLab's growth strategy centers on its proprietary PepMetics technology, which enables drug discovery for targets that were previously difficult to develop. The company operates dual business models: an in-house development model where it nurtures drug candidates and licenses them to pharmaceutical companies, and a co-development model with pharmaceutical partners. Revenue streams include upfront licensing fees, milestone payments at development milestones, and post-launch royalties. While the company does not set fixed sales targets due to its research and development stage, it manages research program count and clinical progress as key metrics, balancing capital allocation and expenses with early commercialization in mind (cash and deposits at fiscal year-end: ¥2,915,572 thousand).

The company prioritizes drug discovery targeting "difficult-to-treat protein-protein interactions" within cells. PRISM BioLab differentiates itself through a drug discovery platform combining three-dimensional small molecule libraries, synthetic capabilities, evaluation equipment, computational chemistry, and AI analysis—enabling end-to-end optimization from hit compound identification to clinical candidate development. The company has clinical-stage programs including E7386 (licensed to Eisai) and PRI-724 (licensed to Ohara Pharmaceutical), demonstrating PepMetics' utility while prioritizing resource allocation to high-probability programs.

The expansion plan aims to stabilize milestone revenue through accumulated co-development contracts while capturing high returns from successful in-house programs. The company operates steering committees with licensees to monitor clinical trial progress and provide guidance, ensuring reliable milestone collection. It also launches new drug discovery programs annually to maintain an optimal pipeline volume for parallel operations while increasing commercialization opportunities. The company is strengthening promotion, upgrading its website, and streamlining sales operations.

For technological innovation, PRISM BioLab continues research and development investment to demonstrate PepMetics' utility while implementing rigorous resource management, including program termination and reallocation as needed. On the human resources front, the company strengthens recruitment and development of diverse researchers to maintain competitive advantage through enhanced technical and execution capabilities. Financially, it focuses on cost management and infrastructure strengthening to support growth, balancing research progress with cash flow management while continuously monetizing its technology.